Arcadia Biosciences, Inc. — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On August 31, 2026, Arcadia Biosciences received notice of delisting or failure to satisfy continued listing rules/standards. The 8-K filing (Item 3.01) indicates the company has been notified of potential transfer of listing or delisting. No specific remediation plan, timeline, or financial details are disclosed in the document excerpt provided.
Why this rating
Delisting is business-threatening for a $5.7M micro-cap; existential threat to public market access and liquidity. Massive relative impact.
Extracted items
- 3.01 delisting notice
- 9.01 exhibits
Tradability signal
NO TRADE
No trade: price $0.47 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.47 ▲ 1.57% | at our read · unknown $0.47 | +10 min · unknown $0.47 ▲ 1.57% | +30 min · unknown $0.47 ▲ 1.57% | +1 hr pending | +4 hrs pending |
The stock had already moved -1.54% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.